These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25525045)

  • 1. Thromboembolic Events in Malignant Pleural Mesothelioma.
    Koksal D; Safak O; Ozcan A; Agackiran Y; Erturk H; Findik G
    Clin Appl Thromb Hemost; 2016 May; 22(4):390-4. PubMed ID: 25525045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
    De León LE; Bravo-Iñiguez CE; Fox S; Tarascio J; Freyaldenhoven S; Lapidot M; Jaklitsch MT; Bueno R
    J Thorac Cardiovasc Surg; 2020 Oct; 160(4):1064-1073. PubMed ID: 32113716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
    Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
    Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
    Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
    Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
    Lin RT; Chang YY; Wang JD; Lee LJ
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
    Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
    Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
    Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytosis in patients with malignant pleural mesothelioma.
    Olesen LL; Thorshauge H
    Cancer; 1988 Sep; 62(6):1194-6. PubMed ID: 3409188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.
    Lin CK; Chang YY; Wang JD; Lee LJ
    Biomed Res Int; 2015; 2015():678598. PubMed ID: 26290869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
    Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
    Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database.
    Bou-Samra P; Chang A; Azari F; Kennedy G; Segil A; Guo E; Marmarelis M; Langer C; Singhal S
    Cancer Med; 2023 Jun; 12(11):12208-12220. PubMed ID: 37062067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
    Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
    Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
    PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.
    Uramoto H; Takiguchi T; Koizumi T; Tanimoto A; Hayashi R; Nakazawa Y; Ito KI; Nakada M; Hirono Y; Nishino Y; Yano S
    J Cancer Res Clin Oncol; 2022 May; 148(5):1153-1158. PubMed ID: 34185142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
    Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N
    Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
    Beckett P; Edwards J; Fennell D; Hubbard R; Woolhouse I; Peake MD
    Lung Cancer; 2015 Jun; 88(3):344-8. PubMed ID: 25863904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.